المؤلفون: Raquel López‐Vilella, Silvia Lozano‐Edo, Patricia Arenas Martín, Pablo Jover‐Pastor, Meryem Ezzitouny, José Sorolla Romero, María Calvo Asensio, Julia Martínez‐Solé, Borja Guerrero Cervera, José Carlos Sánchez Martínez, Víctor Donoso Trenado, Ignacio Sánchez‐Lázaro, Luis Martinez Dolz, Luis Almenar Bonet

المصدر: ESC Heart Failure, Vol 9, Iss 1, Pp 133-145 (2022)
ESC Heart Failure

مصطلحات موضوعية: Ferritin, Iron deficiency, Stroke Volume, Heart failure, Original Articles, Preserved ejection fraction, Ferric carboxymaltose, Ferric Compounds, Ventricular Function, Left, Reduced ejection fraction, RC666-701, Humans, Diseases of the circulatory (Cardiovascular) system, Original Article, Maltose, Cardiology and Cardiovascular Medicine, Retrospective Studies

الوصف: Aims Heart failure (HF) is a proinflammatory disease often associated with the onset of iron deficiency (ID). ID alters mitochondrial function, reducing the generation of cellular energy in skeletal muscle and cardiomyocytes. This study aimed to analyse the response of patients with HF to intravenous iron administration according to the type of HF: preserved ejection fraction (HFpEF) or reduced ejection fraction (HFrEF). Methods and results We conducted a retrospective, single‐centre study of 565 consecutive outpatients diagnosed with HF, recruited over 5 years, who were given intravenous ferric carboxymaltose (FCM) for the treatment of ID [defined as ferritin 0.05). Conclusions Intravenous iron administration appeared to improve ejection fraction and cardiac functional status in outpatients with ID and HF with both preserved and reduced ejection fraction.

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8933f15aa79d2664a68ef42652b1dcf
https://doaj.org/article/663f4ac059874248baec8e9edc3774f6